Here is the design of a clinical trial:

Official Title: Reducing Antibiotics Treatment Duration for Ventilator-Associated Pneumonia

Included conditions:
- Ventilator Associated Pneumonia
- Pneumonia, Bacterial

Study Armgroups:
- {'label': 'Short antibiotic treatment duration for VAP (7 days or less)', 'type': 'ACTIVE_COMPARATOR', 'interventionNames': ['Drug: Reducing Antibiotics treatment duration']}
- {'label': 'Long antibiotic treatment duration for VAP ( 8 days or more)', 'type': 'ACTIVE_COMPARATOR', 'interventionNames': ['Drug: Standard Antibiotics treatment duration']}

Interventions:
- {'type': 'DRUG', 'name': 'Reducing Antibiotics treatment duration', 'description': 'Antibiotics should be stopped from day 3 to 7 if respiratory cultures are negative and the patients fulfill a set of stringent clinical criteria signifying cardiopulmonary stability for 48 hours. If the respiratory cultures are positive, patients who fulfill the same set of clinical criteria should have their antibiotics stopped from day 5 to 7.', 'armGroupLabels': ['Short antibiotic treatment duration for VAP (7 days or less)']}
- {'type': 'DRUG', 'name': 'Standard Antibiotics treatment duration', 'description': 'Participants in the control (long duration) arm will receive standard care, which is antibiotic treatment for at least 8 days with the exact duration decided by the primary physician.', 'armGroupLabels': ['Long antibiotic treatment duration for VAP ( 8 days or more)']}

Primary Outcomes:
- {'measure': 'Proportion of patients who suffered either death or pneumonia recurrence within 60(±5) days of enrolment', 'timeFrame': '60 days'}

Please estimate the sample size based on the assumption: 
A group sequential design with boundaries proposed by Fleming-Harrington-O'Brien is used. The study aims for a power of 80% to conclude non-inferiority with a one-sided alpha risk of 5%. A loss to follow-up rate of up to 10% is anticipated.
Sample size calculation and non-inferiority margin determination
        Mortality after sustaining an episode of VAP has been reported to be 14%â43%âglobally.8 32â39 VAP recurrence rates range from 14% to 40%, with higher incidence in those caused by GNNF bacilli.33 40 41 Mortality observed in these recurrence episodes were 17%â50%.32 33 Based on these, we expect the primary outcome (a composite binary outcome of mortality and VAP recurrence) to occur in 55% of the patients in the standard-of-care arm. We derived an absolute non-inferiority margin of 12% with the fixed-margin method, preserving at least 50% of the efficacy of standard treatment in VAP.42 43 Using a group sequential design adopting the boundaries proposed by Fleming-Harrington-OâBrien, a maximum of 412 patients will be required to achieve a power of 80% to conclude non-inferiority between the two groups with a one-sided Î± risk of 5%.44 As we anticipate a loss to follow-up of up to 10%, we plan to enrol a maximum of 460 patients.